RxDoctor Payments Data

Amanda Reed, DO

Addiction Medicine · Tulsa, OKNPI 1194165258

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (42.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Indivior Inc. accounts for 73.4% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $4,229, more than ten times the $32 reported in 2019. Among addiction medicine clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,500in general payments, 2019–2025

Across 75 payments — averaging $73.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$4K
  • Gilead$392
  • AbbVie$275
  • Alkermes, Inc.$227
  • Viiv Healthcare Company$219
  • Braeburn Inc.$173
  • plus $176 from 4 others

What the payments were for

  • Speaking & faculty fees$2,32842%
  • Travel & lodging$1,10120%
  • Food & beverage$2,07138%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,500 in reported general payments places this provider in the 90th percentile of 20 addiction medicine providers in Oklahoma.

See all addiction medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$3,970
Medicare patients
19
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala20$83,054
DovatoDolutegravir Sodium/Lamivudine13$44,414
VemlidyTenofovir Alafenamide13$18,437
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl25$3,458
Gabapentin30$661
Hydroxyzine Hcl13$431
Duloxetine Hcl21$192
Quetiapine Fumarate11$105
Sertraline Hcl24$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Vemlidy$392$101,49133 claims
Viiv Healthcare CompanyDovato$219$44,41413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 addiction medicine providers in Oklahoma.

Other addiction medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →